scispace - formally typeset
K

Katherine Dawson

Researcher at Biogen Idec

Publications -  59
Citations -  4254

Katherine Dawson is an academic researcher from Biogen Idec. The author has contributed to research in topics: Dimethyl fumarate & Multiple sclerosis. The author has an hindex of 20, co-authored 59 publications receiving 3846 citations.

Papers
More filters
Journal ArticleDOI

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

TL;DR: In patients with relapsing-remitting multiple sclerosis, both BG-12 regimens, as compared with placebo, significantly reduced the proportion of patients who had a relapse, the annualized relapse rate, the rate of disability progression, and the number of lesions on MRI.
Journal ArticleDOI

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

TL;DR: In patients with relapsing-remitting multiple sclerosis, BG-12 (at both doses) and glatiramer acetate significantly reduced relapse rates and improved neuroradiologic outcomes relative to placebo.
Journal ArticleDOI

BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety

TL;DR: BG-12 may have cytoprotective and anti-inflammatory properties that contribute to its efficacy among patients with RRMS, and findings from phase 2 and 3 studies further support BG-12 as an effective initial therapy.
Journal ArticleDOI

Manufacturer's Response to Case Reports of PML

TL;DR: Ermis et al. as mentioned in this paper reported progressive multifocal leukoencephalopathy (PML) in two patients with psoriasis who were being treated with Fumaderm (Biogen Idec) or a compounded version of fumaric acid esters (FAEs) referred to as Psorinovo (compounding pharmacy, Mierlo-Hout).